Novel carboxypeptidase A6 (CPA6) mutations identified in patients with juvenile myoclonic and generalized epilepsy
Related Experiment Video
Updated: Apr 14, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Matthew R Sapio1, Monique Vessaz2, Pierre Thomas3
1Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY, United States of America.
Insights
Two novel Carboxypeptidase A6 (CPA6) mutations, Arg36His and Asn271Ser, are linked to generalized epilepsy. These genetic alterations impair CPA6 enzyme activity and extracellular matrix levels, suggesting a role in epilepsy predisposition.
Area of Science:
- Biochemistry and Molecular Biology
- Neurogenetics
- Enzymology
Background:
- Carboxypeptidase A6 (CPA6) is a secreted peptidase involved in extracellular matrix processing, with expression in the brain.
- Previous studies linked CPA6 gene mutations to temporal lobe epilepsy and febrile seizures.
- The role of CPA6 in generalized epilepsy syndromes remained largely unexplored.
Purpose of the Study:
- To investigate the potential role of CPA6 mutations in juvenile myoclonic epilepsy (JME).
- To identify and characterize novel CPA6 variants in epilepsy patients.
- To assess the functional impact of identified mutations on CPA6 activity and localization.
Main Methods:
- Screening of CPA6 gene in patients with juvenile myoclonic epilepsy.
- In silico modeling of identified mutations (Arg36His, Asn271Ser) within the CPA6 structure.
- In vitro expression studies in HEK293T cells to assess enzyme activity, extracellular matrix (ECM) levels, and secretion kinetics via pulse-chase experiments.
Main Results:
- Two novel missense mutations, Arg36His and Asn271Ser, were identified in patients with generalized epilepsy, including JME.
- The Asn271Ser mutation completely abolished CPA6 enzymatic activity.
- The Arg36His mutation reduced CPA6 levels in the ECM by approximately 50% and decreased overall ECM-associated CPA6.
- Secretion kinetics were similar for wild-type and mutant CPA6, but total secreted amounts were reduced for mutants.
Conclusions:
- The identified CPA6 mutations (Arg36His and Asn271Ser) are deleterious and associated with generalized epilepsy.
- Asn271Ser and Arg36His mutations impair CPA6 function through distinct mechanisms: loss of enzymatic activity and reduced ECM localization, respectively.
- These findings strengthen the evidence implicating CPA6 gene mutations in the predisposition to various epilepsy types.
Abstract:
Carboxypeptidase A6 (CPA6) is a peptidase that removes C-terminal hydrophobic amino acids from peptides and proteins. The CPA6 gene is expressed in the brains of humans and animals, with high levels of expression during development. It is translated with a prodomain (as proCPA6), which is removed before secretion. The active form of CPA6 binds tightly to the extracellular matrix (ECM) where it is thought to function in the processing of peptides and proteins. Mutations in the CPA6 gene have been identified in patients with temporal lobe epilepsy and febrile seizures. In the present study, we screened for CPA6 mutations in patients with juvenile myoclonic epilepsy and identified two novel missense mutations: Arg36His and Asn271Ser. Patients harboring these mutations also presented with generalized epilepsy. Neither of the novel mutations was found in a control population. Asn271 is highly conserved in CPA6 and other related metallocarboxypeptidases. Arg36 is present in the prodomain and is not highly conserved. To assess structural consequences of the amino acid substitutions, both mutants were modeled within the predicted structure of the enzyme. To examine the effects of these mutations on enzyme expression and activity, we expressed the mutated enzymes in human embryonic kidney 293T cells. These analyses revealed that Asn271Ser abolished enzymatic activity, while Arg36His led to a ~50% reduction in CPA6 levels in the ECM. Pulse-chase using radio-labeled amino acids was performed to follow secretion. Newly-synthesized CPA6 appeared in the ECM with peak levels between 2-8 hours. There was no major difference in time course between wild-type and mutant forms, although the amount of radiolabeled CPA6 in the ECM was lower for the mutants. Our experiments demonstrate that these mutations in CPA6 are deleterious and provide further evidence for the involvement of CPA6 mutations in the predisposition for several types of epilepsy.
More Related Videos
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Inborn Errors of Metabolism
Antiepileptic Drugs: Glutamate Antagonists
Lysosomal Hydrolases